Fig. 1From: Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from SwitzerlandMean time interval in days between injections of aflibercept and ranibizumab in the months 1–12 following incident treatment. Light blue: ranibizumab; dark blue: afliberceptBack to article page